Celio Kussumoto

Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)

Nizar M. Tannir, Maria Nirvana Formiga, Konstantin Penkov, Nikolay Kislov et autres

PURPOSE Bempegaldesleukin (BEMPEG) is a pegylated interleukin (IL)-2 cytokine prodrug engineered to provide controlled and sustained activation of the clinically validated IL-2 pathway, with the goal of preferentially activating and expanding effector CD8+ T cells and natural killer cells over immunosuppressive regulator …

us, br, ru (code pays fourni par la source)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou et autres

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with …

ca, us, gb, es, kr, fr, my, ua, au (code pays fourni par la source)

A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial

Gilberto de Castro, J. G. M. Segalla, Sérgio Jobim Azevedo, Carlos José Coelho de Andrade et autres

br (code pays fourni par la source)

Real World Treatment Patterns And Resource Use For Advanced Non-Small Cell Lung Cancer In Brazilian Private Institutions

C.S.d.R. Baldotto, ES Mascarenhas, M.T. Laloni, EG Wiermann et autres

br (code pays fourni par la source)

Molecular Marker Analyses of Egfr and Kras from the Randomized Phase Ii Study of Nimotuzumab in Locally Advanced Esophageal Cancer (Nice Trial)

Gilberto de Castro, N. Skare, J. G. M. Segalla, Sérgio Jobim Azevedo et autres

br, mx (code pays fourni par la source)